Anti-Sense Video
PEACHBRAIN!
Comments on "Anti-Sense"
cutie!
?
cutie!
?
Recent Police Force News:
Related Videos:
Lanoderm from Isis pharma.flv
www.natural-biocare.com Pioneering antisense drug discovery We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity. With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $880 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements. Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent <b>...</b>
www.natural-biocare.com Pioneering antisense drug discovery We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity. With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $880 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements. Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent <b>...</b>Palomar - Let's Talk Plans
Palomar - Let's Talk Plans. This track has really grown on me. Dale should do a video for it!
Palomar - Let's Talk Plans. This track has really grown on me. Dale should do a video for it!TEEN DERM from ISISPHARMA
natural-herbs-market.com Pioneering antisense drug discovery We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity. With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $880 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements. Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent <b>...</b>
natural-herbs-market.com Pioneering antisense drug discovery We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity. With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $880 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements. Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent <b>...</b>
Global Rheumatoid Arthritis Therapeutics Market to Exceed $23.12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Rheumatoid Arthritis Therapeutics markets. The world market for rheumatoid arthritis biologic therapeutics is projected to exceed $23.12 billion by 2015. The market comprises of a sizeable, growing patient population encompassing untreated patients, patients taking DMARDs, patients taking anti-TNF therapies, and patients taking non-anti-TNF therapies. Among all therapies, anti-pro-inflammatory drugs that block the action of TNF-alpha (known as anti-TNF biologics) dominate the market.
Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligon
NittoPhase™ HL Loaded up to 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs and Increase Yields
First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy
Researchers from Children's National Medical Center and colleagues in Tokyo publish results, video of first successful trial in dogs with Duchenne muscular dystrophy
Arrowhead Releases New Report Assessing State of Personalized Medicine Market
The era of Personalized Medicine is set to revolutionize the healthcare industry. As our knowledge of genetics and molecular biology rapidly expands, a personalized approach to medical care is becoming increasingly important.
Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
Dalton Pharma Services announces the renewal of its Chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd. Under the agreement Dalton will continue to provide chemistry services in support of Boehringer's pharmaceutical development programs.
Scholarship Honours York University Chemistry Professor
Peter Pekos, president and CEO of Dalton Pharma Services, has established a new scholarship to benefit chemistry students at York University in Toronto, in honour of his former mentor and business partner, Dr. Douglas Butler.
Global Prostate Cancer Therapeutics Market to Reach $4.8 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Development of new therapies and drugs for prostate cancer is likely to supplement, rather substitute the prevailing drugs or therapies, such as chemotherapy, radiation therapy, hormonal therapy and surgery, and propel sales in global prostate cancer therapeutics market to $4.8 billion by 2015.
Industry Experts and Global Regulators to Discuss Oligonucleotide-Based Therapeutics Issues
The Drug Information Association (DIA), in collaboration with the FDA, Oligonucleotide Therapeutics Society, Health Canada, and the American Association of Pharmaceutical Scientists, will host the 2nd Conference on Oligonucleotide-based Therapeutics (September 22 - 24; Falls Church, VA).
antisensedrugs.com
The antisense drug resource
adultstemcell.org
The adult stem cell forum
